Tuesday, December 7, 2021

Tag: Acorda Therapeutics

Acorda Therapeutics Announces Initiation of Phase 2 Trial of Treatment for Spinal Cord Injury

AC105 improved motor function after spinal cord injury in preclinical studies ARDSLEY, N.Y.--(BUSINESS WIRE)--Sep. 25, 2013-- Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the first...

Working2Walk 2011, Anthony Caggiano (Acorda)

The Challenges of Chondroitinase Development for Spinal Cord Injury